Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: KDM4 inhibition targets breast cancer stem cells [RNA-Seq]

PROVIDER: PRJNA376575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5280802_1.fastq.gz	Fastqsanger.gz
	SRR5280802_2.fastq.gz	Fastqsanger.gz
	SRR5280803_1.fastq.gz	Fastqsanger.gz
	SRR5280803_2.fastq.gz	Fastqsanger.gz
	SRR5280804_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Homo sapiens

Project description:KDM4 inhibition targets breast cancer stem cells

| PRJNA375805 | ENA

Homo sapiens

Project description:KDM4 inhibition targets breast cancer stem cells [ChIP-Seq]

| PRJNA376389 | ENA

KDM4 inhibition targets breast cancer stem cells

Project description:KDM4 inhibition targets breast cancer stem cells

| PRJNA376573 | ENA

E-GEOD-35031

Project description:Gene expression underlying estrogen receptor activation versus inhibition in breast cancer cells

2025-01-24 | E-GEOD-35031 | ExpressionAtlas

E-MTAB-6998

Project description:RNA-seq of mesenchymal stromal cells cultured in the presence of breast cancer cell secretomes

2025-01-23 | E-MTAB-6998 | ExpressionAtlas

E-MTAB-5230

Project description:RNA-seq of WTAP knockdown human pluripotent stem cells during the exit from pluripotency induced by Activin/Nodal inhibition

2025-01-23 | E-MTAB-5230 | ExpressionAtlas

KDM4 inhibition targets breast cancer stem cells

Project description:Cancer progression is associated with alterations of epigenetic regulators such as histone-lysine demethylases 4 (KDM4)2-5. During breast cancer therapy, classical treatments fail to address resistant cancer stem cell populations6-10. Here, we identified a novel KDM4 inhibitor (KDM4(i)) with unique preclinical characteristics. KDM4(i) is a highly potent pan KDM4 inhibitor that specifically blocks the demethylase activity of KDM4A, B, C, and D but not that of the other members of the KDM family. We validated the KDM4(i) anti-tumoral properties under conditions recapitulating patient tumors. Therefore, we established a method to isolate and grow triple-negative breast cancer stem cells (BCSCs) from individual patient tumors after neoadjuvant chemotherapy. Limiting dilution orthotopic xenografts of these BCSCs faithfully regenerate original patient tumor histology and gene expression. KDM4(i) blocks proliferation, sphere formation and xenograft tumor growth of BCSCs. Importantly, KDM4(i) abrogates expression of EGFR, a driver of therapy-resistant triple-negative breast tumor cells11, via inhibition of the KDM4A demethylase activity. Taken together, we present a unique BCSC culture system as a basis for therapeutic compound identification and demonstrate that KDM4 inhibition is a new therapeutic strategy for the treatment of triple-negative breast cancer.

2018-04-10 | GSE95042 | GEO

E-GEOD-31138

Project description:Identifying novel anti-angiogenic targets in human breast cancer

2025-01-24 | E-GEOD-31138 | ExpressionAtlas

E-MTAB-5243

Project description:Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells

2025-01-23 | E-MTAB-5243 | ExpressionAtlas

E-MTAB-5244

Project description:Ampliseq transcriptomic array of REF seq. genes in Snai1 knock out triple negative breast cancer cells

2025-01-23 | E-MTAB-5244 | ExpressionAtlas